Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-102 in advanced solid tumors
NCT05055518Phase 1Suspended
- Sponsor
- Apollomics, Inc.
- Start
- Aug 2021
- Primary completion
- Oct 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APL-102 in solid tumor (advanced stage), sponsored by Apollomics, Inc. Primary endpoints: Dose Limited Toxicity at 36 days and Adverse Events at 1 year. Started Aug 2021; status: suspended.
02
Drugs
APL-102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05055518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055518.